Purpose: The aim of this study was to compare local recurrence (LR) rates in patients with ductal carcinoma in situ (DCIS) at the surgical margins after breast-conserving surgery (BCS). Methods: This single-center, retrospective study included patients diagnosed with invasive ductal carcinoma (IDC) who underwent BCS at National Cancer Center between 2014 and 2020. Patients with DCIS at the surgical margin were eligible for inclusion. Those who did not undergo re-excision received whole-breast radiotherapy with an escalated tumor bed boost of 15 Gy in five fractions. The 5-year breast cancer recurrence rates were estimated using the Kaplan-Meier method, and prognostic factors were evaluated using univariate and multivariate Cox proportional hazards regression models. Results: Among the 235 eligible patients, 115 underwent re-excision (Re-excision + group), and 120 did not (Re-excision − group). With a median follow-up of 5.0 years (range, 3.1–6.6 years), the 5-year LR rate was 6.1% in the Re-excision + group and 5.8% in the Re-excision − group (log-rank p = 0.9). Re-excision was not significantly associated with differences in LR rates in multivariate analysis. Conclusion In cases where DCIS was present at the surgical margin after BCS, re-excision was not associated with a lower LR rate compared with dose-escalated radiotherapy.This study did not assess late radiation-related toxicities, such as breast fibrosis, which are important considerations for treatment decision-making. These findings should be interpreted with caution because of the retrospective design and limited event rate. Further prospective studies are warranted to determine optimal management strategies.

The purpose of this study was to examine whether ginsenoside Rg3 (GRg3) could improve learning and memory impairments and inflammatory reactions induced by injecting lipopolysaccharide (LPS) into the brains of rats. The effects of GRg3 on proinflammatory mediators in the hippocampus and the underlying mechanisms of these effects were also investigated. Injection of LPS into the lateral ventricle caused chronic inflammation and produced deficits in learning in a memory-impairment animal model. Daily administration of GRg3 (10, 20, and 50 mg/kg, i.p.) for 21 consecutive days markedly improved the LPS-induced learning and memory disabilities demonstrated on the step-through passive avoidance test and Morris water maze test. GRg3 administration significantly decreased expression of pro-inflammatory mediators such as tumor necrosis factor-alpha, interleukin-1beta, and cyclooxygenase-2 in the hippocampus, as assessed by reverse transcription-polymerase chain reaction analysis and immunohistochemistry. Together, these findings suggest that GRg3 significantly attenuated LPS-induced cognitive impairment by inhibiting the expression of pro-inflammatory mediators in the rat brain. These results suggest that GRg3 may be effective for preventing or slowing the development of neurological disorders, including Alzheimer's disease, by improving cognitive and memory functions due to its anti-inflammatory activity in the brain.
Alzheimer Disease ; Animals ; Brain ; Cyclooxygenase 2 ; Hippocampus ; Immunohistochemistry ; Inflammation ; Interleukin-1beta ; Lateral Ventricles ; Learning* ; Memory* ; Models, Animal ; Nervous System Diseases ; Rats* ; Tumor Necrosis Factor-alpha ; Water

Baicalein (BA), a plant-derived active flavonoid present in the root of Scutellaria baicalensis, has been widely used for the treatment of stress-related neuropsychiatric disorders including depression. Previous studies have demonstrated that repeated restraint stress disrupts the activity of the hypothalamic-pituitary-adrenal (HPA) axis, resulting in depression. The behavioral and neurochemical basis of the BA effect on depression remain unclear. The present study used the forced swimming test (FST) and changes in brain neurotransmitter levels to confirm the impact of BA on repeated restraint stress-induced behavioral and neurochemical changes in rats. Male rats received 10, 20, or 40 mg/kg BA (i.p.) 30 min prior to daily exposure to repeated restraint stress (2 h/day) for 14 days. Activation of the HPA axis in response to repeated restraint stress was confirmed by measuring serum corticosterone levels and the expression of corticotrophin-releasing factor in the hypothalamus. Daily BA administration significantly decreased the duration of immobility in the FST, increased sucrose consumption, and restored the stress-related decreases in dopamine concentrations in the hippocampus to near normal levels. BA significantly inhibited the stress-induced decrease in neuronal tyrosine hydroxylase immunoreactivity in the ventral tegmental area and the expression of brain-derived neurotrophic factor (BDNF) mRNA in the hippocampus. Taken together, these findings indicate that administration of BA prior to the repeated restraint stress significantly improves helpless behaviors and depressive symptoms, possibly by preventing the decrease in dopamine and BDNF expression. Thus, BA may be a useful agent for the treatment or alleviation of the complex symptoms associated with depression.
Animals ; Brain ; Brain-Derived Neurotrophic Factor ; Corticosterone ; Depression ; Dopamine ; Flavanones* ; Hippocampus ; Hypothalamus ; Male ; Neurons ; Neurotransmitter Agents ; Rats* ; RNA, Messenger ; Physical Exertion ; Scutellaria baicalensis ; Sucrose ; Tyrosine 3-Monooxygenase ; Ventral Tegmental Area